Here are four observations:
1. The increasing interest in tissue-engineered and stem cell products will boost the market’s growth.
2. Regenerative medicines’ potential in restoring diseased organs will elevate the market.
3. Cell therapy captured 80 percent of the U.S. regenerative medicine market in 2015.
4. Dominate market vendors include Acelity, Mesoblast, Organogenesis, Reprocell and Stryker.
More articles on biologics:
Smith & Nephew to purchase regenerative medicine company for $210M: 3 points
Anika Therapeutics appoints new chief human resources officer: 5 points
Dr. Alok Sharan presents results of novel surgical procedure at the NuVasive Spine Summit
